Skip to main content

Advertisement

SpringerLink
Log in

Sustained beneficial effect of intravenous bisphosphonates after their discontinuation in children

  • Original Article
  • Published:
Pediatric Nephrology Aims and scope Submit manuscript

Abstract

We studied if the beneficial effects of bisphosphonates are maintained after their discontinuation, and whether adverse effects may develop. Seventeen children in whom I.V. bisphosphonates were discontinued for at least 12 months were included. Fracture rate (FR), skeletal pain, bone mineral density of total body (TB) and spine L2–4, skeletal radiographs, bone markers and kidney functions were compared between: (a) before treatment, (b) end of treatment, and (c) last follow-up. Mean treatment duration was 22±2 months (6–43) and follow-up 26±2 months (18–44). FR (mean ± SD) decreased from 0.74±0.21/year before treatment to 0.35±0.11/year after treatment and 0.20±0.09/year at follow-up (p<0.05). Three children had bone pain before treatment, six during treatment and none at end of follow-up (p<0.05). TB Z-score increased from −1.24±0.50 at baseline to −0.37±0.44 at end of treatment and −0.39±0.37 at follow-up (p<0.05). Spinal Z-score increased from −1.65±0.57 to −0.34±0.56 and 0.19±0.49, respectively (p<0.05). Bone turnover markers showed sustained effect of bisphosphonates. No adverse effects on kidney functions or skeletal radiographs were noted. We conclude that I.V. bisphosphonates continue to exert their beneficial effect for a mean of 26±2 months after their discontinuation; therefore, once therapeutic goals are achieved, the medication can be withheld, followed by periodic re-evaluation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Srivastava T, Alon US (2003) The role of bisphosphonates in diseases of childhood. Eur J Pediatr 162:735–751

    Article  CAS  PubMed  Google Scholar 

  2. Steelman J, Zeitler P (2003) Treatment of symptomatic pediatric osteoporosis with cyclic single-day intravenous pamidronate infusions. J Pediatr 142:417–423

    Article  CAS  PubMed  Google Scholar 

  3. Glorieux FH, Bishop NJ, Plotkin H, Chabot G, Lanoue G, Travers R (1998) Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med 339:947–952

    Article  CAS  PubMed  Google Scholar 

  4. Matarazzo P, Lala R, Masi G, Andreo M, Altare F, de Sanctis C (2002) Pamidronate treatment in bone fibrous dysplasia in children and adolescents with McCune-Albright syndrome. J Pediatr Endocrinol Metab 15(Suppl 3):929–937

    CAS  PubMed  Google Scholar 

  5. Bianchi ML, Cimaz R, Bardare M, Zulian F, Lepore L, Boncompagni A, Galbiati E, Corona F, Luisetto G, Giuntini D, Picco P, Brandi ML, Falcini F (2000) Efficacy and safety of alendronate for the treatment of osteoporosis in diffuse connective tissue diseases in children: a prospective multicenter study. Arthritis Rheum 43:1960–1966

    Article  CAS  PubMed  Google Scholar 

  6. Sakkers R, Kok D, Engelbert R, van Dongen A, Jansen M, Pruijs H, Verbout A, Schweitzer D, Uiterwaal C (2004) Skeletal effects and functional outcome with olpadronate in children with osteogenesis imperfecta: a 2-year randomised placebo-controlled study. Lancet 363:1427–1431

    Article  CAS  PubMed  Google Scholar 

  7. Letocha AD, Cintas HL, Troendle JF, Reynolds JC, Cann CE, Chernoff EJ, Hill SC, Gerber LH, Marini JC (2005) Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short-term functional improvement. J Bone Miner Res 20:977–986

    Article  CAS  PubMed  Google Scholar 

  8. Gatti D, Antoniazzi F, Prizzi R, Braga V, Rossini M, Tato L, Viapiana O, Adams S (2005) Intravenous neridronate in children with osteogenesis imperfecta: a randomized controlled study. J Bone Miner Res 20:758–763

    Article  CAS  PubMed  Google Scholar 

  9. Falk MJ, Heeger S, Lynch KA, DeCaro KR, Bohach D, Gibson KS, Warman ML (2003) Intravenous bisphosphonate therapy in children with osteogenesis imperfecta. Pediatrics 111:573–578

    Article  PubMed  Google Scholar 

  10. Acott PD, Wong JA, Lang BA, Crocker JF (2005) Pamidronate treatment of pediatric fracture patients on chronic steroid therapy. Pediatr Nephrol 20:368–373

    Article  PubMed  Google Scholar 

  11. Ezra A, Golomb G (2000) Administration routes and delivery systems of bisphosphonates for the treatment of bone resorption. Adv Drug Deliv Rev 42:175–195

    Article  CAS  PubMed  Google Scholar 

  12. Marx RE, Sawatari Y, Fortin M, Broumand V (2005) Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 63:1567–1575

    Article  PubMed  Google Scholar 

  13. Whyte MP, Wenkert D, Clements KL, McAlister WH, Mumm S (2003) Bisphosphonate-induced osteopetrosis. N Engl J Med 349:457–463

    Article  CAS  PubMed  Google Scholar 

  14. Barri YM, Munshi NC, Sukumalchantra S, Abulezz SR, Bonsib SM, Wallach J, Walker PD (2004) Podocyte injury associated glomerulopathies induced by pamidronate. Kidney Int 65:634–641

    Article  PubMed  Google Scholar 

  15. Markowitz GS, Fine PL, Stack JI, Kunis CL, Radhakrishnan J, Palecki W, Park J, Nasr SH, Hoh S, Siegel DS, D’Agati VD (2003) Toxic acute tubular necrosis following treatment with zoledronate (Zometa). Kidney Int 64:281–289

    Article  CAS  PubMed  Google Scholar 

  16. Woo SB, Hellstein JW, Kalmar JR (2006) Systematic review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 144:753–761

    Article  CAS  PubMed  Google Scholar 

  17. Hogler W, Yap F, Little D, Ambler G, McQuade M, Cowell C (2004) Short-term safety assessment in the use of intravenous zoledronic acid in children. J Pediatr 145:701–704

    Article  CAS  PubMed  Google Scholar 

  18. Leonard MB, Propert KJ, Zemel BS, Stallings VA, Feldman HI (1999) Discrepancies in pediatric bone mineral density reference data: potential for misdiagnosis of osteopenia. J Pediatr 135:182–188

    Article  CAS  PubMed  Google Scholar 

  19. Leib ES, Lewiecki EM, Binkley N, Hamdy RC (2004) International Society for Clinical Densitometry. Official positions of the International Society for Clinical Densitometry. South Med J 97:107–110

    Article  PubMed  Google Scholar 

  20. Zoledronate (Zometa) (2001) Med Lett Drugs Ther 43:110–111

    Google Scholar 

  21. Van Beek E, Hoekstra M, van de Ruit M, Lowik C, Papapoulos S (1994) Structural requirements for bisphosphonates actions in vitro. J Bone Miner Res 9:1875–1882

    Article  CAS  PubMed  Google Scholar 

  22. Chavassieux PM, Arlot ME, Reda C, Wei L, Yates AJ, Meunier PJ (1997) Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. J Clin Invest 100:1475–1480

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Seikaly MG, Kopanati S, Salhab N, Waber P, Patterson D, Browne R, Herring JA (2005) Impact of alendronate on quality of life in children with osteogenesis imperfecta. J Pediatr Orthop 25:786–791

    Article  PubMed  Google Scholar 

  24. Vyskocil V, Pikner R, Kutilek S (2005) Effect of alendronate therapy in children with osteogenesis imperfecta. Joint Bone Spine 72:416–423

    Article  PubMed  Google Scholar 

  25. Hogler W, Yap F, Little D, Ambler G, McQuade M, Cowell CT (2004) Short-term safety assessment in the use of intravenous zoledronic acid in children. J Pediatr 145:701–704

    Article  CAS  PubMed  Google Scholar 

  26. Cremers SC, Papapoulos SE, Gelderblom H, Seynaeve C, den Hartigh J, Vermeij P, van der Rijt CC, van Zuylen L (2005) Skeletal retention of bisphosphonate (pamidronate) and its relation to the rate of bone resorption in patients with breast cancer and bone metastases. J Bone Miner Res 20:1543–1547

    Article  CAS  PubMed  Google Scholar 

  27. Lasseter KC, Porras AG, Denker A, Santhanagopal A, Daifotis A (2005) Pharmacokinetic considerations in determining the terminal elimination half-lives of bisphosphonates. Clin Drug Invest 25:107–114

    Article  CAS  Google Scholar 

  28. Rossini M, Gatti D, Zamberlan N, Braga V, Dorizzi R, Adami S (1994) Long-term effects of a treatment course with oral alendronate of postmenopausal osteoporosis. J Bone Miner Res 9:1833–1837

    Article  CAS  PubMed  Google Scholar 

  29. Landman JO, Hamdy NA, Pauwels EK, Papapoulos SE (1995) Skeletal metabolism in patients with osteoporosis after discontinuation of long-term treatment with oral pamidronate. J Clin Endocrinol Metab 80:3465–3468

    Article  CAS  PubMed  Google Scholar 

  30. Langman CB, Arwady AL, Price H (2005) Bone after cessation of alendronate use in children with fracturing osteoporosis [abstract]. J Bone Miner Res 20:S245

    Google Scholar 

  31. Khosla S, Melton LJ, Dekutoski MB, Achenbach SJ, Oberg AL, Riggs BL (2003) Incidence of childhood distal forearm fractures over 30 years. JAMA 290:1479–1485

    Article  CAS  PubMed  Google Scholar 

  32. Cooper C, Dennison E, Leufkens HGM, Bishop N, Van Staa TP (2004) Epidemiology of childhood fractures in Britain: a study using the general practice research database. J Bone Miner Res 19:1976–1981

    Article  PubMed  Google Scholar 

  33. Zeitlin L, Rauch F, Plotkin H, Glorieux FH (2003) Height and weight development during four years of therapy with cyclical intravenous pamidronate in children and adolescents with osteogenesis imperfecta types I, III, and IV. Pediatrics 111:1030–1036

    Article  PubMed  Google Scholar 

  34. Brumsen C, Hamdy N, Papapoulos SE (1997) Long-term effects of bisphosphonates on the growing skeleton:studies of young patients with severe osteoporosis. Medicine (Baltimore) 76:266–283

    Article  CAS  Google Scholar 

  35. Rudge S, Hailwood S, Horne A, Lucas J, Wu F, Cundy T (2005) Effects of once-weekly oral alendronate on bone in children on glucocorticoid treatment. Rheumatology 44:813–818

    Article  CAS  PubMed  Google Scholar 

  36. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL (2004) Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 62:527–534

    Article  PubMed  Google Scholar 

  37. American Dental Association (2006) Dental management of patients receiving oral bisphosphonate therapy - Expert panel recommendations. June. https://doi.org/www.ada.org/prof/resources/topics/topics_osteonecrosis_recommendations.pdf

  38. Plotkin H, Bruzoni M, Coughlin S, Lerner G, Allbery S, Schroeder B, Heldt K, Grovas L, Kreikemeier R (2005) Low doses of pamidronate for the treatment of osteoporosis in children with cerebral palsy [abstract]. J Bone Miner Res 20:S280

    Google Scholar 

  39. Garnero P, Shih WJ, Gineyts E, Karpf DB, Delmas PD (1994) Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab 79:1693–1700

    CAS  PubMed  Google Scholar 

  40. Federico G, Baroncelli GI, Vanacore T, Fiore L, Saggese G (2003) Pubertal changes in biochemical markers of growth. Horm Res 60:46–51

    CAS  PubMed  Google Scholar 

  41. Van der Sluis IM, Hop WC, van Leeuwen JP, Pols HA, de Muinck Keizer-Schrama SM (2002) A cross-sectional study on biochemical parameters of bone turnover and vitamin d metabolites in healthy dutch children and young adults. Horm Res 57:170–179

    PubMed  Google Scholar 

  42. Mora S, Prinster C, Proverbio MC, Bellini A, de Poli SC, Weber G, Abbiati G, Chiumello G (1998) Urinary markers of bone turnover in healthy children and adolescents: age-related changes and effect of puberty. Calcif Tissue Int 63:369–374

    Article  CAS  PubMed  Google Scholar 

  43. Tommasi M, Bacciottini L, Benucchi A, Passeri A, Saracini D, D’Agata A, Cappelli G (1996) Serum biochemical markers of bone turnover in healthy infants and children. Int J Biol Markers 11:159–164

    Article  CAS  PubMed  Google Scholar 

  44. Khosla S, Kleerekoper M (2003) Biochemical markers of bone turnover. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. American Society for Bone and Mineral Research, Washington, D.C., pp. 166–172

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Bone and Mineral Disorders Clinic, Section of Pediatric Nephrology, The Children’s Mercy Hospital and Clinics, University of Missouri-Kansas City School of Medicine, Kansas City, MO, USA

    Kim M. Waterhouse, Ari Auron, Tarak Srivastava, Connie Haney & Uri S. Alon

  2. Section of Pediatric Nephrology, The Children’s Mercy Hospital, 2401 Gillham Road, Kansas City, MO, 64108, USA

    Uri S. Alon

Authors
  1. Kim M. Waterhouse
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ari Auron
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Tarak Srivastava
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Connie Haney
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Uri S. Alon
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Uri S. Alon.

Additional information

Supported by the Sam and Helen Kaplan Research Fund in Pediatric Nephrology.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Waterhouse, K.M., Auron, A., Srivastava, T. et al. Sustained beneficial effect of intravenous bisphosphonates after their discontinuation in children. Pediatr Nephrol 22, 282–287 (2007). https://doi.org/10.1007/s00467-006-0306-0

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00467-006-0306-0

Keywords

Search

Navigation